Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2022; 14(10): 537-545
Published online Oct 26, 2022. doi: 10.4330/wjc.v14.i10.537
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation
Ibragim Al-Seykal, Abhishek Bose, Parag A Chevli, Zeba Hashmath, Nitish Sharma, Ajay K Mishra, Douglas Laidlaw
Ibragim Al-Seykal, Nitish Sharma, Ajay K Mishra, Douglas Laidlaw, Department of Medicine, Division of Cardiology, Saint Vincent Hospital, Worcester, MA 01608, United States
Abhishek Bose, Department of Medicine, Division of Cardiology, University of Massachusetts Chan School of Medicine, Worcester, MA 01608, United States
Parag A Chevli, Section on Hospital Medicine, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, United States
Zeba Hashmath, Department of Medicine, Division of Cardiology, East Carolina University, Greenville, NC 27858, United States
Author contributions: Al-Seykal I and Bose A contributed to the conceptual design of the study; Al-Seykal I, Bose A, Mishra A and Hashmath Z independently screened the medical records and extracted the data; Chevli P did the statistical analysis; Al-Seykal I, Mishra A, Hashmath Z and Sharma N contributed to write-up and submission of the study; Bose A, Mishra A, and Laidlaw D reviewed the final manuscript; all authors reviewed and agreed with the final content of the article.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of MetroWest Medical Center.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ajay K Mishra, FACP, MBBS, MD, Academic Fellow, Assistant Professor, Department of Medicine, Division of Cardiology, Saint Vincent Hospital, 123 Summer Street, Worcester, MA 01608, United States. ajay.mishra@stvincenthospital.com
Received: May 29, 2022
Peer-review started: May 29, 2022
First decision: June 8, 2022
Revised: June 18, 2022
Accepted: September 6, 2022
Article in press: September 6, 2022
Published online: October 26, 2022
Processing time: 144 Days and 0.2 Hours
Core Tip

Core tip: We investigated the role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in preventing recurrence of atrial arrhythmias following cryoballoon ablation (CBA) for paroxysmal atrial fibrillation (AF). Outcomes of 103 patients were evaluated in a retrospective chart review. Preablation treatment with an ACEI or ARB had no influence on recurrence of AA following CBA for paroxysmal AF. To our knowledge, this study is the first of its kind to examine the effect of ACEI/ARB use in this exclusive subset of patients.